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Transcription factor ZNF25 is associated
with osteoblast differentiation of human
skeletal stem cells
Natalie A. Twine1, Linda Harkness2,4, Moustapha Kassem1,2,3† and Marc R. Wilkins1*†
Abstract
Background: The differentiation of human bone marrow derived skeletal stem cells (known as human bone
marrow stromal or mesenchymal stem cells, hMSCs) into osteoblasts involves the activation of a small number
of well-described transcription factors. To identify additional osteoblastic transcription factors, we studied gene
expression of hMSCs during ex vivo osteoblast differentiation.
Results: Clustering of gene expression, and literature investigation, revealed three transcription factors of interest –
ZNF25, ZNF608 and ZBTB38. siRNA knockdown of ZNF25 resulted in significant suppression of alkaline phosphatase
(ALP) activity. This effect was not present for ZNF608 and ZBTB38. To identify possible target genes of ZNF25, we
analyzed gene expression following ZNF25 siRNA knockdown. This revealed a 23-fold upregulation of matrix
metallopeptidase 1 and an 18-fold upregulation of leucine-rich repeat containing G protein-coupled receptor 5
and RAN-binding protein 3-like. We also observed enrichment in extracellular matrix organization, skeletal system
development and regulation of ossification in the entire upregulated set of genes. Consistent with its function as
a transcription factor during osteoblast differentiation of hMSC, we showed that the ZNF25 protein exhibits
nuclear localization and is expressed in osteoblastic and osteocytic cells in vivo. ZNF25 is conserved in tetrapod
vertebrates and contains a KRAB (Krueppel-associated box) transcriptional repressor domain.
Conclusions: This study shows that the uncharacterized transcription factor, ZNF25, is associated with differentiation
of hMSC to osteoblasts.
Keywords: Osteogenesis, Mesenchymal stem cells, Osteoblasts, ZNF25, Human transcription factors
Background
Adult human skeletal stem cells (also known as bone
marrow stromal or mesenchymal stem cells, hMSCs) are
present in the bone marrow stroma. They are defined by
their ability to both self-renew and differentiate into
mesoderm-specific lineage cells including osteoblasts,
adipocytes and chondrocytes [1, 2]. These two characteris-
tics make hMSCs a valuable resource in the fields of
cellular therapeutics and regenerative medicine [3, 4]. The
potential clinical use of hMSC therapy has been examined
in an increasing number of clinical conditions, including
treating children with osteogenesis imperfecta [5–7] as well
as bone repair of non-healed fractures and large bone
defects [4, 8, 9].
Lineage-specific differentiation of hMSCs into osteo-
blasts (OBs) is dependent on a number of microenviron-
mental cues [1, 10]. In vitro OB differentiation of hMSCs
is induced by a mixture of hormones (e.g. dexamethasone,
calcitriol) and chemicals (e.g. organic phosphate donors
such as β-glycerophosphate) and the expression of mature
OB phenotype takes place through a series of develop-
mental stages: cell expansion and proliferation, cell com-
mitment to OB, and differentiation into pre-osteoblasts
followed by maturation of osteoblasts which synthesize
the bone matrix and promote mineralization [10, 11].
Phases of OB differentiation and establishment of the
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osteoblastic phenotype are controlled by a set of transcrip-
tion factors.
A number of transcription factors (TFs) have been
demonstrated to play important roles in OB differenti-
ation and function. Runt domain-containing transcrip-
tion factor (RUNX2) is the major TF in both osteoblast
commitment and differentiation [10–12]. Homozygous
deletion of this gene in mice resulted in a complete ab-
sence of osteoblasts and bone formation [12]. Another
TF, Osterix (OSX or SP7), specifically expressed by oste-
oblasts, is positively regulated by and acts downstream
of RUNX2 [10]. Activating transcription factor 4 (ATF4)
plays an important role in mature osteoblasts, and it in-
teracts with RUNX2 to regulate the expression of osteo-
calcin [10]. Other TFs that have been shown to regulate
osteoblast differentiation include: the AP1 family of
proteins; LEF/TCF (via Wnt signalling); homeobox
proteins MSX2, HOXA2 and DLX5; helix-loop-helix
(bHLH) proteins HES, HEY, TWIST and HAND2; and
CCAAT/enhancer-binding proteins (C/EBPs) [13]. Al-
though a number of TFs have been identified to be
important in osteoblastic differentiation, this is a very
small subset of all documented human TFs. Vaquerizas
et al. [14] have generated a list of 1391 manually curated,
sequence-specific DNA-binding human TFs.
Many reported human transcription factors are unchar-
acterized in terms of their biological functions [14]. It is
plausible that some of the uncharacterized TFs are im-
portant regulators of osteoblast differentiation. In this
study, we employed genome-wide expression profiling
to identify TFs which were differentially expressed
between undifferentiated hMSCs and their differenti-
ated osteoblastic cell progeny. By clustering these TFs
using self-organizing maps (SOMs), and by literature
analysis, we identified three TFs as novel candidates
with possible regulatory functions in osteoblast differ-
entiation. We further explored the role of one of these
candidates, ZNF25. siZNF25 knockdown experiments
showed regulatory effects on osteoblast differentiation.
Microarray analysis of siZNF25 deficient osteoblastic
cells, identified three highly up-regulated genes, LGR5,
MMP1 and RANBP3L, and we propose these as pos-
sible targets of ZNF25. We also report that ZNF25 has
a KRAB domain, a transcriptional repressor, which is
conserved in tetrapod vertebrates.
Methods
Cell culture
As a model for primary hMSCs, we employed hMSC-
TERT cells (subclone hMSC-TERT4). The source and
generation of hMSC-TERT cells are described in [15].
These exhibit a stable cellular and molecular phenotype
comparable to that of primary hMSCs [16]. hMSC-TERT
cells were routinely cultured in standard media (SM)
(MEM (Invitrogen) with 10 % v/v FBS (PAA, Pasching,
Austria). The generation and characterization of hMSC-
TERT cells were as described in detail in [15].
Osteoblast differentiation
Ex vivo osteoblast differentiation was performed
using osteoblast induction medium containing β-
glycerophosphate (10 mM; Calbiochem-Merck), L-
ascorbic acid-2-phosphate (50 μg/ml; Sigma-Aldrich,
Brøndby, Denmark), dexamathasone (10nM; Sigma-
Aldrich) and calcitriol (1,25 hydroxy-vitamin D3; 10nM) in
standard medium (SM). Media were changed every 3 days
until day 15.
Alkaline phosphatase activity measurements
Alkaline phosphatase (ALP) activity was quantified as pre-
viously described [17], using a 1 mg/ml solution of P-
nitrophenylphosphate (Sigma-Aldrich, Brøndby, Denmark)
in 50 mM NaHCO3 with 1 mM MgCl2, pH 9.6, at 37 °C
for 20 min. Activity was stopped using 3 M NaOH and the
absorbance of each reaction (max = 405 nm) was measured
using a FLUOstar Omega plate reader (BMG Laboratories,
Ramcon A/S, Birkerod, Denmark). ALP activity was nor-
malized to cell number, as determined using a CellTiter-
Blue Cell Viability assay, according to manufacturer’s
instructions (Promega, Nacka, Sweden).
Cytochemical staining
Cells undergoing osteogenic differentiation were stained
at days 6, 10 and 15 for ALP and days 10 and 15 for
alizarin red (AZR) as previously described [18]. Elution
of AZR staining was performed using 10 % cetylpyri-
dium for 1 h at room temperature; 25–100 μl was then
removed to a 96 well plate and read on a FLUOstar
Omega plate reader at 595 nm emission wavelength.
Immunohistochemical staining
Routine protocols [18] were used to stain for ZNF25
(Novus Biologics antibody H00219749-B01). Briefly,
immunocyto-chemical staining was performed using
DAKO PowerVision + HRP according to manufacturer’s
instructions. The primary antibody was diluted in
ChemMate Antibody diluent (S2022, Dako, Glostrup,
Denmark) and processed on an automatic slide processor
(Techmate500, Dako, Glostrup, Denmark). DAB was used
as the chromogen and the slides were counterstained with
haematoxylin. Analysis was carried out on an IX50
Olympus microscope using OlympusDP Software v3.1
(Olympus, Essex, UK) or a Leica DM4500 (Leica, Wetzlar,
Germany) using the Surveyor Turboscan Mosaic acquisi-
tion imaging analysis system v5.04.01 (Objective Imaging
Ltd, Cambridge, UK). To assess localization of the ZNF25
protein, cells undergoing OB induction were passaged and
replated 2 days prior to fixation (4 % formalin) in
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osteoblast induction medium. This ensured that both
the cytoplasm and nuclear localization could be easily
visualised. Following fixation, cells were blocked and
permeabilised (1 % FBS, 0.1 % Triton X-100 in PBS) be-
fore overnight incubation with ZNF25 antibody. Anti-
rabbit alexa-fluor 488 (Invitrogen) was utilized as a
secondary antibody and cells were counterstained with
Phalloidin pre-conjugated with TRITC (5nM, Sigma)
and Hoechst H33342 (0.1ug/ml, Sigma). Image acquisi-
tion was performed on a Perkin Elmer Operetta High
Content Imaging System.
Matrix mineralisation assay
Deposition of hydroxyapatite was measured using the
OsteoImage™ Bone Mineralization Assay (Lonza) according
to manufacturer’s instructions. Briefly, cells were plated in
96 well plates at 20,000/cm2 and induced in osteoblast in-
duction medium for 15 days with media changed every
third day. Following fixation (4 % formalin for 10 min
at RT), wells were washed in Lonza wash buffer before
staining with OsteoImageTM staining reagent conju-
gated to 488 for 30 min at RT. Post-staining, wells were
washed in wash buffer before being read on a FLUOstar
Omega plate reader set at 488 nm emission wavelength.
In vivo heterotopic bone formation
hMSC-TERT (0.5 × 106) were suspended into single cells
and combined with 40 mg hydroxy-apatite tricalcium
phosphate as previously reported (HA/TCP, 0.5–1 mm
granules, Biomatlante/Zimmer, Vigneux de Bretagne,
France) [19–21]. Non-induced cells were incubated
overnight in HA/TCP before implantation into the
dorsolateral area of immune compromised mice
(NOD.CB17-Prkdcscid/J) for 8 weeks. After retrieval, im-
plants were fixed overnight in 4 % formalin, washed in
PBS before decalcification in formic acid for 3–5 days.
Following embedding in wax, four serial sections were
cut at three depths with 100um between each group and
sections from each group were stained with haematoxylin
and eosin, or human specific-vimentin antibody (AbCam).
siRNA-based knock down experiments
LNA-modified Silencer® Select siRNAs targeting the
desired genes (ZNF608, ZBTB38 and ZNF25) and non-
targeted negative controls 1 and 2 were purchased from
Ambion (Invitrogen). Validation of siRNA data was done
using a second Silencer® Select siRNA for ZBTB38 and
ZNF608, and one Mission siRNA (Sigma-Aldrich) for
ZNF25. Reverse transfection of siRNA was performed
using LipofectamineTM 2000 (Invitrogen) according to
the manufacturer’s instructions. siRNA transfections
were carried at as described in [3, 16].
Affymetrix microarray gene expression analysis
hMSC-TERT cells were cultured and induced to differ-
entiate into osteoblasts as described [20]. At 0, 3, 6, 9
and 12 days after induction, total RNA was extracted
using TRIzol (Invitrogen) as previously reported [22].
Five hundred ng of total RNA from each sample were
used for biotin-labeled cRNA production using a linear
amplification kit (Ambion). First- and second-strand
cDNA syntheses were performed from 8 μg total RNA
using the SuperScript Choice System (Life-Technologies,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. Subsequent hybridization and scanning of
the Affymetrix arrays were performed as described pre-
viously [23]. The biotinylated targets were hybridized to
HuGene 1.0ST v 1 Affymetrix oligonucleotide arrays.
Expression measures were generated and normalized
using the RMA procedure implemented in the Partek
Genomics Suite version 6.12.0307. Values were then log2
transformed before further analysis. Affymetrix HuGene
2.0ST arrays were used for siZNF25 knock down and cor-
responding control samples. Partek Genomics Suite ver-
sion 6.6 was used to analyse the resultant microarray data.
Illumina bead chip microarray
hMSC-TERT cells were cultured and induced to differ-
entiate into osteoblasts as described [20]. At days 0, 1, 7
and 13 after induction, total RNA was extracted from
each of three independent cell cultures. At 90–100 %
confluence, highly purified total cellular RNA was iso-
lated using an RNeasy Kit (QIAGEN Nordic, West Sus-
sex, UK) according to the manufacturer’s instructions. A
total of 500 ng of total RNA from each sample was used
for biotin-labeled cRNA production using a linear ampli-
fication kit (Ambion).
Hybridization, washing, Cy3-streptavidin staining and
scanning were performed on the Illumina BeadStation
500 platform (Illumina) according to the manufacturer’s
instruction. cRNA samples were hybridized onto Illu-
mina HT12 V4 BeadChips. Analyses of gene expression
data were carried out using the GenomeStudio software
(v2011.1). Raw data were normalized using the quantile
normalisation and then filtered for significant expression
on the basis of negative control beads. A p-value of < 0.01
was used as a cut-off for detection of significance.
Differential gene expression analysis and significance
testing was done using the ‘lumi’ BioConductor package
[24]. After being checked for quality, data was trans-
formed using the ‘variance stabilizing transform’. Data
was quantile normalized and probes that passed the de-
tection p-value threshold (p < 0.01), for at least one time
point, were selected for further analysis. Differentially
expressed genes were identified by a 2-way ANOVA,
and Benjamini-Hochberg multiple testing correction.
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Extraction of curated transcription factors
Transcription factors were extracted from Illumina and
Affymetrix datasets using the list of 1391 curated TFs
detailed in [14]. This was done using Partek Genomics
Suite (v 6.12.0307). Some TFs on the list were updated
to their current Ensembl Identifiers. A small number of
TFs were not present on the Affymetrix Gene ST array,
and were thus excluded from the analysis.
Self organising map-based cluster analysis
Self organising map (SOM) cluster analysis was per-
formed using Partek Genomics Suite (v 6.12.0307). For
the Illumina array dataset, the average gene expression
of the three replicates at each time point was used as the
gene expression measure. Gene expression data was
shifted to a mean of zero before cluster generation to
aid in the viewing of cluster profiles. The number of
clusters in each map was varied between 25 and 81, in
order to identify the optimum number of clusters for a
particular dataset. The optimum number of clusters was
achieved when each cluster displayed a single gene expres-
sion trend across the time course. For the Affymetrix array
dataset, this was 64 clusters and for the Illumina array
dataset it was 36.
RNA isolation and real-time quantitative PCR
Total RNA was isolated using TRIzol (Invitrogen) as
previously reported (15). For real-time quantitative PCR,
data were normalised to the geometric mean of four
reference genes (β-Actin, B2M, HPRT, UBC1) and ana-
lysed using a comparative Ct method. Primer sequences
were designed using the Primer-BLAST tool (http://
www.ncbi.nlm.nih.gov/tools/primer-blast/). Primer se-
quences are listed below in Table 1.
Western blot analysis
Western blot analyses were carried out on control
and differentiated OB cells as previously reported
[20]. The antibodies used were ZNF25 (Novus Bio-
logics antibody H00219749-B01) and alpha-tubulin
(Sigma-Aldrich) whereas goat anti Rabbit IgG-HRP
(SantaCruz Biotechnology, Inc, Heidelberg, Germany)
was used as the secondary antibody.
BLAST analysis and domain alignment
Evolutionary analysis of ZNF25 protein sequence was
performed using the blastp program available at http://
blast.ncbi.nlm.nih.gov/Blast.cgi. Domain alignments of
ZNF25 orthologs were generated using the ‘Illustrator for
Biological Sequences’ tool (version 1) [25].
Results
hMSC-TERT differentiate into osteoblastic cells in vitro
and form heterotopic bone in vivo
hMSC-TERT differentiate readily into osteoblastic cells,
evidenced by enhanced expression of osteoblast marker
genes (ALPL, BGLAP, COL1A1) (Fig. 1a), increased alka-
line phosphatase activity and formation of in vitro miner-
alized matrix stained positive for Alizarin red during
differentiation (Fig. 1b). hMSC-TERT cells are also able to
form heterotopic bone when implanted subcutaneously,
with hydroxyapatite tricalcium phosphate (HA/TCP), in
immune deficient mice (Fig. 1c).
Transcription factors associated with in vitro osteoblast
differentiation
Two microarray datasets were generated during in vitro
osteoblast differentiation of hMSC-TERT: Illumina HT12-
v4 arrays at four time points (days 0, 1, 7, 13) and Affyme-
trix HuGene 1.0 STv1 arrays at six time points (days 0, 3,
6, 9, 12). These datasets will be referred to as the ‘Illumina’
and ‘Affymetrix’ datasets. The Illumina time course dataset
was filtered to extract expression patterns for 1391
Human TFs, as curated by Vaquerizas et al. [14]. This pro-
duced a list of 1141 probes, mapping to 738 unique TFs.
One hundred and forty nine TFs showed expression
changes of 0.71 > FC > 1.40 between day 0 and day 13 post
OB induction, with an adjusted p value of 0.20. This
threshold was used because RUNX2 and ATF4, the
major regulators of osteoblastogenesis, displayed a
fold change of 1.48 (p adj = 0.141, p unadj = 0.048) and
1.48 (p adj = 0.18, p unadj = 0.065) in the Illumina
Table 1 Forward and reverse primer sequences for real-time quantitative PCR assays
Gene Forward primer 5’-3’ Reverse primer 5’-3’
ZNF25 CCTGGGGCTGCCAGCTAAGGT CAGGGAAGCCCCGATGTGGAA
ZBTB38 CACAGAAGCCCTCTAGCCAAG AGCAGGAAAGCCCTCCTAGA
ZNF608 GTGGTCAATGTCACGTGGAG AGCCCTCTGGACTCTGTGAA
RUNX2 TGGTTACTGTCATGGCGGGTA TCTCAGATCGTTGAACCTTGCTA
COL1A1 AGGGCTCCAACGAGATCGAGATCCG TACAGGAAGCAGACAGGGCCAACGTCG
ALPL ACGTGGCTAAGAATGTCATC CTGGTAGGCGATGTCCTTA
BGLAP CATGAGAGCCCTCACA AGAGCGACACCCTAGAC
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dataset, respectively. For the Affymetrix dataset, 1380
TFs were extracted, using the same curated set from
Vaquerizas et al. [14].
Transcription factors cluster according to temporal
expression during in vitro osteoblast differentiation
To identify groups of genes that showed similar tem-
poral expression patterns during in vitro osteoblastic dif-
ferentiation, self-organizing maps (SOMs) were used
(Fig. 2). For the Affymetrix TF dataset, six clusters
showed distinct up or down regulation across the time-
course (Fig. 2a). The up-regulated clusters i, ii and iii
contained 17, 8 and 13 genes respectively whereas the
down-regulated clusters iv, v and vi contained 16, 17 and
9 genes, respectively. Interestingly, another cluster showed
a decrease in gene expression from day 0 to day 3,
followed by an increase in gene expression to day 12. The
TFs contained within all clusters are listed in Table 2.
We examined all the clusters containing upregulated
genes, for the presence of TFs that have known roles in
osteoblast differentiation. Cluster i contained 17 TFs, of
which seven have been previously documented to be in-
volved in osteoblastogenesis in mouse and rat models.
These include AHR, DDIT3, EGR2, RORA, SALL4, ZEB2
and ZNF385A [26] [27–30]. Cluster ii contained
RUNX2, along with TFs EPAS1, HES1,NR4A3, PRDM1,
STAT4 and ZBTB16; these are known to either be in-
volved in osteoblastic differentiation or bone homeosta-
sis, as direct regulators or via an interaction with a
regulator [31–36]. Cluster iii contained 13 TFs, all of
which have previously been documented to be involved
in hMSC differentiation into either osteoblasts, adipo-
cytes or chondrocytes (e.g. BCL6, EBF1, FOXO1, KLF15,
KLF5, MKX, NFIA, NPAS2, OSR2, SIX1, STAT2, THRB
and TSC22D3) [13] [37–44].
We further examined the upregulated clusters for TFs
that are currently not associated with differentiation and
development. This revealed a total of 11 TFs of interest;
ten of which were in cluster i. The majority of these are
zinc finger proteins (ZNF25, ZNF117, ZNF235, ZNF345,
ZNF354A, ZNF 449, ZNF493, ZNF566) and two are zinc
finger and BTB domain-containing proteins, ZBTB1 and
ZBTB38. The final TF was in cluster ii, which was zinc
finger protein ZNF608.
The Illumina TF dataset was also subjected to the
same process of SOM clustering as described for the
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Fig. 1 hMSC-TERT differentiate into osteoblastic cells in vitro and form heterotopic bone in vivo. a RT-PCR experiments show gene expression of
canonical osteoblastic markers ALP, COL1A1 and BGLAP in hMSC-TERT cells at day 0 and day 15 post-induction of OB differentiation. The error
bars (S.E.M.) represent 4 independent biological replicates. The y axis represents expression relative to a set of housekeeping genes. b Alkaline
phosphatase (ALP) activity in hMSC-TERT cells at days 0 and 6 post-OB induction. Alizarin red (AZR) staining for matrix mineralisation at days 0 and 15
post-OB induction. c In vivo bone-formation assay was performed by implanting hMSC-TERT, mixed with hydroxyapatite–tricalcium phosphate
(HA/TCP), subcutaneously into immune-deficient mice for 8 weeks. Sections were stained with hematoxylin (pink osteoid) and eosin (blue nuclei)
(left hand image) or human- specific vimentin demonstrating human origin of osteoid and osteocytes (right hand image). The scale bar =100 μm
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Fig. 2 Transcription factor expression profiles across an osteoblast differentiation time course. a Transcription factor expression levels were
extracted from Affymetrix microarrays and clustered with self organizing maps. The Y axis of each cluster cell is normalised, log2 gene expression,
while the X axis displays the six time points in days (day 0,1,3,6,9,12). Clusters displaying a distinct change in expression profile across time are
outlined in the map and shown to the right. There are three upregulated clusters, outlined in red: i (17 genes), ii (8 genes) and iii (13 genes).
There are three downregulated clusters, outlined in blue: iv (16 genes), v (17 genes) and vi (9 genes). The cluster (vii), outlined in green, contains
18 genes and showed a decrease in expression during early differentiation, followed by an upregulation in expression from day 3 to day 12.
b Transcription factor expression levels were extracted from Illumina microarrays and clustered with self organizing maps. The Y axis of each cluster cell
is the normalised, log2 gene expression, while the X axis displays the four time points in days (day 0,1,7,13). Clusters displaying a distinct change in
expression profile across time are outlined. These clusters are expanded in the right hand side of the image. There are five upregulated clusters, labelled
i (14 genes), ii (15 genes), iii (17 genes), iv (13 genes) and v (18 genes), outlined in red. There are three downregulated clusters labelled vi (9 genes),
vii (15 genes) and viii (16 genes) and these are outlined in blue. c Gene expression profiles across the OB differentiation time-course for transcription factors
ZNF25, ZBTB38 and ZNF608. These are extracted from the (i) Affymetrix array data and (ii) Illumina array data. The time points in days post-OB induction are
labeled on the X axis, while the Y axis displays normalized gene expression values. For the Affymetrix array plot (i), the fold change values between day 12
and day 0 are: ZNF25 (1.9 FC), ZBTB38 (2.6 FC) and ZNF608 (5.3 FC). For the Illumina array plot (ii), the fold change and p values are for day 13 versus day 0:
ZNF25 (1.55 FC, p= 0.067), ZBTB38 (1.66 FC, p= 0.025) and ZNF608 (1.41 FC, p= 0.0013). The Illumina array TF plot (ii) displays an average of the 3 biological
replicates at each time point
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Affymetrix dataset. In this case, this produced 36 clus-
ters of TF expression profiles. Each cluster contained
between 3 and 44 genes. Five clusters showed up-
regulation of TFs across the time-course (labeled i-v in
Fig. 2b), while three clusters showed a distinct down-
regulation (labeled vi, vii and viii in Fig. 2b). The TF
content and gene expression information of each labeled
cluster is detailed in Table 3. The total of 77 TFs in clus-
ters i to v were examined to identify which TFs have pre-
viously been implicated in MSC differentiation, bone
formation or related mesodermal differentiation processes
such as adipogenesis. Fifty nine of the TFs were found to
be differentiation-associated, whereas 16 TFs were identi-
fied as potentially novel osteoblast-differentiation associ-
ated TF candidates. These included ZNF181, ZNF697,
ZNF295, ZNF22, ZNF532, ZNF302, ZNF217, ZNF721,
ZNF25, ZNF608, ZNF419, ZNF558 and ZNF627, along
with two zinc finger- and BTB-domain containing pro-
teins ZBTB38 and ZBTB40 and zz-type zinc finger-
containing protein ZZZ3.
Identification of three novel TFs associated with in vitro
osteoblast differentiation
We employed a number of criteria to select TFs for fur-
ther analysis. As shown in Fig. 3, the TFs had to be
present in up-regulated SOM clusters in both Affymetrix
and Illumina analyses, the TFs had to be previously un-
reported in association with hMSC differentiation, bone
formation or related processes and, finally, the TFs had
to exhibit a statistically significant increase in expression
during in vitro OB differentiation. Three TFs satisfied
these criteria, namely zinc finger protein 25 (ZNF25),
zinc finger- and BTB-domain containing protein 38
(ZBTB38) and zinc finger protein 608 (ZNF608). The
fold change increase in gene expression and p-values
showed by these during differentiation for day 13 versus
day 0 were ZNF25 (1.55 FC, p = 0.067), ZBTB38 (1.66
FC, p = 0.025) and ZNF608 (1.41 FC, p = 0.0013) in the
Illumina dataset (Fig. 2c). We further validated gene ex-
pression profiles of ZNF25, ZNF608 and ZBTB38,
employing quantitative RT-PCR in independent bio-
logical experiments (Fig. 4a–c). Similar to the microarray
data, all three TFs displayed a temporal increase in gene
expression with maximal expression during the late
phase (days 10–15) of in vitro osteoblast differentiation
(Fig. 4a–c). There was also a statistically significant dif-
ference in qPCR expression measurements between day
0 and day 15 for ZNF25 and ZNF608. However, ZBTB38
did not display a significant difference. (Student’s t-
test, ZNF25 p = 0.0027, ZNF608 p = 0.0089 and ZBTB38
p = 0.3353).
siRNA knock-down of ZNF25 affects osteoblast
differentiation
The temporal gene expression pattern of the candidate
TFs suggested a role in osteoblast differentiation of
Table 2 Members of transcription factor clusters identified during osteoblast differentiation, derived from the Affymetrix dataset
Upregulated clusters Downregulated clusters V-shaped cluster
Cluster i Cluster ii Cluster iii Cluster iv Cluster v Cluster vi Cluster vii
AHR EPAS1 BCL6 AFF3 DLX1 OSR1 BACH1
DDIT3 HES1 EBF1 ARNTL2 DLX2 RARB BHLHE40
EGR2 NR4A3 FOXO1 CREB3L2 E2F1 SMAD9 CEBPG
RORA PRDM1 KLF15 CTCFL EGR1 TSHZ1 CREB5
SALL4 RUNX2 KLF5 DRAP1 EZH2 DPF1 ETV1
ZBTB1 STAT4 MKX FOSL1 FOXM1 TFAP2A ETV4
ZBTB38 ZBTB16 NFIA LHX9 GATA2 RARG ETV5
ZEB2 ZNF608 NPAS2 MXD3 ID1 ZNF93 FOXQ1
ZNF117 OSR2 NFATC4 KLF4 ZNF519 HIVEP2
ZNF235 SIX1 PAX6 MEF2C JUN
ZNF25 STAT2 PRDM16 MYBL1 NR1D1
ZNF345 THRB RFX2 MYBL2 NR1D2
ZNF354A TSC22D3 TP63 SNAI1 TBX3
ZNF385A WHSC1 SOX9 TFAM
ZNF449 ZNF90 TCF19 ZNF295
ZNF493 TCF7 ZNF326
ZNF566 ZNF695 ZNF643
ZNF678
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Fig. 3 The method used to identify ZNF25, ZNF608 and ZBTB as candidates of interest in osteogenesis. The gene expression profiles for a number of
transcription factors were extracted from two microarray datasets (Illumina and Affymetrix), using a curated set of human transcription factors (TFs).
Self Organising Maps (SOMs) were then used to cluster the subsets of TFs according to temporal expression pattern. TFs that were upregulated in
SOM clusters were then further screened based on literature analysis. Upregulated TFs that were previously unreported to be associated with hMSC
differentiation, bone formation or related processes were selected for further analysis. In addition, the TF expression profiles extracted from the Illumina
array dataset were analysed for differential expression. TFs that were significantly differentially expressed between undifferentiated hMSC and
differentiated OB were selected for further analysis. Three TFs satisfied all of these selection criteria, namely ZNF25, ZBTB38 and ZNF608
Table 3 Members of transcription factor clusters identified during osteoblast differentiation, derived from the Illumina dataset
Upregulated clusters Downregulated clusters
Cluster i Cluster ii Cluster iii Cluster iv Cluster v Cluster vi Cluster vii Cluster viii
ZBTB16 AHR CDC5L ZBTB38 ZNF181 E2F4 SOX9 TFAP2A
KLF9 FOXN2 SNAI2 BMP2 ZNF697 ID3 DLX1 MYBL1
EPAS1 TSC22D3 TGIF1 FOXC1 ATF4 ZNF207 HOXB2 ELF4
FOXO1 ZFP36L1 FOS CEBPG JUN NFIC NFIX ID2
MYC NFIA STAT2 E2F5 MXD1 TSHZ1 PITX1 E2F2
SOX4 NFE2L2 NFIB EGR1 NR1D2 MXD4 SRF DRAP1
STAT4 FOSB NR2F1 DDIT3 FOXJ3 PRRX2 TEAD4 TFDP1
CEBPB ZNF22 CEBPZ MAFB SATB2 ZNF503 NR2F6 ATF5
NFIL3 HBP1 SMAD5 ZEB2 TBX3 EZH2 NFE2 KLF2
IFI16 SIX4 ZNF217 ZBTB40 MYNN TCF25 SOX18
NR4A2 ZNF532 RERE ZZZ3 ZNF608 ZNF668 ZNF395
BATF EBF1 ZBTB20 ZNF295 ZNF419 ZNF408 MXD3
ZBTB33 ELF1 BBX MKX ZNF622 ZNF672 OSR1
FOXQ1 HIF1A ZNF462 ZNF558 ZNF511 ID1
ZNF302 ZNF721 ZNF627 CREB3L2 THRA
ZNF25 TBX15 FOXM1
PRDM1 TCF12
KLF11
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hMSC. To test this hypothesis, we examined the effects
of siRNA-mediated knockdown of each of the TFs on
ALP activity, as a marker of the osteoblastic phenotype.
A statistically significant decrease in ALP activity was
seen on knockdown of ZNF25 (p < 0.005, Fig. 4d), rela-
tive to that of the scrambled siRNA control. By contrast,
siRNA-mediated knockdown of ZNF608 and ZBTB38
did not show a reduction on ALP activity. On the other
hand, knockdown of ZNF608 actually showed a statistically
significant increase (p = 0.00002) in ALP activity. For the
purposes of this study we further focused our analyses only
on ZNF25.
ZNF25 protein expression increases during osteoblast
differentiation
We investigated the temporal expression of the ZNF25
protein and its localization in cells and in human bone
tissue biopsies. Similar to ZNF25 gene expression, the
Fig. 4 Validation of expression increases for ZNF25, ZBTB38 and ZNF608 during OB differentiation in hMSC-TERT cells. a-c Quantitative RT-PCR showing
expression of ZNF25, ZBTB38 and ZNF608 in hMSC-TERT cells during OB differentiation. The Y axis represents mean expression relative to a set of
housekeeping genes (refer to Methods). The X axis represents days post-induction of OB differentiation. Error bars reflect SEM from 4 biological
replicates. d Alkaline phosphatase activity in hMSC-TERT cells after siRNA knockdown of TFs ZNF25, ZBTB38 and ZNF608. The alkaline phosphatase
activity was measured at day 6 post-OB induction for all samples, where the y axis reflects units of P-nitrophenylphosphate normalised to cell number.
The NI siControl refers to hMSC-TERT cells not induced for OB differentiation and transfected with a scrambled control siRNA. The OB siControl refers
to hMSC-TERT cells induced for OB differentiation and transfected with a scrambled control siRNA. A highly significant reduction in ALP activity was
observed between siZNF25 and OB siControl (p = 7.89 × 10−7) and a highly significant increase in ALP activity was observed between siZNF608 and the
OB siControl (p = 1.68 × 10−6); these are marked by four asterisks. There was no significant change in alkaline phosphatase activity between siZBTB38
and OB siControl
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production of the ZNF25 protein was found to increase
during in vitro osteoblast differentiation, at days 6, 10
and 15 (Fig. 5a). In keeping with its role as a transcrip-
tion factor, in vitro staining of hMSC-TERT revealed it
to have nuclear and perinuclear localization (Fig. 5b). In
human femoral neck bone biopsies, immunostaining lo-
calized the ZNF25 protein to active osteoblastic surfaces
as well as osteocytes (Fig. 5c).
ZNF25 siRNA knockdown causes increase in expression of
genes relevant to osteoblast differentiation
ZNF25 contains a KRAB domain, and is therefore likely
to act as a transcriptional repressor [45]. To gain insight
into the possible targets of ZNF25 and confirm its re-
pressor activity, we used microarrays to analyse the gene
expression of control and ZNF25 knockdown cells
(siZNF25) at days 0 and day 14, post-osteoblast differen-
tiation (Fig. 6). At day 0, 50 genes were identified as dif-
ferentially expressed between siZNF25 and control
samples (3 upregulated and 47 downregulated using
two - fold change and FDR <0.05 as threshold). At day
14, by contrast, 520 genes were identified as differen-
tially expressed between siZNF25 and control samples
(347 upregulated, 173 downregulated and using two -
fold change and FDR < 0.05 as threshold). Since ZNF25
contains a KRAB domain and is likely to be a transcrip-
tional repressor, any genes that show marked upregula-
tion could be of functional significance. At day 0, there
were no genes that showed dramatic upregulation in
siZNF25 cells. However at day 14 there were four
genes that showed 18-fold to 26-fold upregulation. The
most significantly upregulated gene in differentiated
siZNF25 cells relative to control was matrix metallo-
peptidase 1 (MMP1, FC = 23.00, pval = 6.09 × 10−6).
The next most upregulated genes were leucine-rich re-
peat containing G protein-coupled receptor 5 (LGR5,
FC = 18.59, pval = 5.77 × 10−7) and RAN binding pro-
tein 3-like (RANBP3L, FC = 18.08, pval = 1.81 × 10−9).
We also observed a very high upregulation in unanno-
tated transcript cluster, 17118303 (FC = 26.05, pval =
7.49 × 10−6). On further investigation it was found that
this transcript cluster maps to chromosomal location:
chr7:94058513–94060553. This chromosomal location
corresponds to exon 52 of the COL1A2 gene, however
no other probes for this gene were upregulated to
this level.
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Fig. 5 Expression and localisation of the ZNF25 protein. a Protein levels of ZNF25 increase during OB differentiation of hMSCs, as revealed by
western blotting and quantitation of the same blot. b ZNF25 is localised to the nucleus and perinuclear area after immunocyto-chemical staining
during OB differentiation. Left, middle and right images show hMSC-TERT cells at day 10 of OB differentiation; ZNF25 was detected by immunostaining
(green) (left image), cells were counterstained with Phalloidin pre-conjugated with TRITC (yellow/orange, cytoplasmic actin) and Hoechst H33342
(blue, nucleus) (middle and right image). This confirms the localisation of ZNF25 to the nucleus and perinuclear region as highlighted in the right image.
The dotted rectangle in the middle image indicates area that is magnified to form the right image. The white scale bars in the bottom left of the images
indicate a distance of 100 μm in left and middle image, and 30 μm in the right image. c Antibody-based localisation of ZNF25 in the human femoral
neck bone demonstrates highly positive brown staining in the osteocytes (left) and in osteoblast surfaces (middle and in higher magnification on right).
The dotted rectangle in the middle image indicates the area that is magnified to form the right image. There is a small amount of non-specific staining
in other cell types in this image. The black scale bars in the top left of the images indicate a distance of 50 μm for the left and middle images, and
16 μm for the right image
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DAVID functional enrichment analysis [46, 47] of the
520 genes differentially expressed at day 14 post-OB
induction showed enrichment for: ‘extracellular matrix
organisation’ (p value = 2.9 × 10−11, FDR = 4.6 × 10–8), ‘os-
sification’ (p value = 2.08 × 10−5, FDR = 0.035), ‘bone de-
velopment’ (p value = 3.9 × 10−5, FDR = 0.06), ‘skeletal
system development’ (p value = 2.69 × 10−4, FDR = 0.459)
and ‘regulation of ossification’ (p value = 0.0049, but with
a higher FDR of 8.08). The genes involved in these en-
richment categories are all upregulated (Fig. 6). Analyses
of the same gene sets by ReviGO [48] and GOrilla [49]
yielded functionally similar results (data not shown).
Background used for all enrichment analyses was the
Affymetrix Human Gene 2.0 ST array gene set.
ZNF25 is conserved but found only in tetrapod
vertebrates
The evolutionary conservation of ZNF25 was then inves-
tigated. ZNF25 was highly conserved amongst mammals,
with the top 250 top-ranked proteins from BLAST
analysis being from mammalian species. The mouse pro-
tein ZFP9, for example, showed 79 % sequence identity
with an E value = 0.0 and appeared as a true ortholog of
ZNF25 via a reciprocal BLAST with all human proteins.
Use of the GABLAM tool [50] also identified ZNF25
mammalian homologs in seven species. These observa-
tions are consistent with results in the NCBI homologene
database, that details ZNF25 orthologs for mammalian
species, including Pan troglodytes, Macaca mulatta, Canis
lupus, Bos taurus, Mus musculus and Rattus norvegicus.
For other species, we observed full length matches to
the chicken protein ZFP302 (44 % sequence identity, E
value = 8 × 10-126) and Xenopus tropicalus zinc finger
protein 180 (44 % sequence identity, E value = 7 × 10−137).
However these are unlikely to be true orthologs as they
did not identify ZNF25 via reciprocal BLAST. Whilst a
single KRAB domain was present in each protein, dif-
ferent numbers of C2H2 domains were present, with 12
in human but 11 in chicken and Xenopus. In zebrafish,
there was partial homology to the ZNF25 C2H2 domain
GO Term Genes
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RECK, IBSP, 
COL4A2, ELN, 
COL3A1, CCDC80, 
NID1, ECM2, 
COL5A2, COL5A1, 
EMILIN1, 
TNFRSF11B, 
SMOC1, FBLN5, 
COL1A2, COL1A1, 
COL11A1, 
ADAMTS2 
skeletal 
system 
development 
IBSP, PDLIM7, 
FBN1, COL3A1, 
TGFB3, MGP, 
SPARC, COL5A2, 
IGSF10, INHBA, 
TNFRSF11B, 
COL1A2, SORT1, 
COL1A1, AXIN2, 
COL11A1, RUNX2, 
CDH11 
regulation of 
ossification 
PDLIM7, PTGER4, 
ENPP1, TGFB3, 
MGP, AXIN2, 
RUNX2 
Fig. 6 ZNF25 siRNA knockdown increases the expression of MMP1, LGR5, RANBP3L and other osteoblastic differentiation genes. Volcano plot
representing the 512 genes most differentially expressed between siZNF25 knockdown and control hMSCs at day 14 post-OB induction. The siZNF25/
control fold change for each gene is represented on the x axis, with the corresponding p value represented on the y axis (expressed as –log(p value)).
Genes which have the Gene Ontology (GO) annotation ‘extracellular matrix organisation’ are coloured in red. Genes with GO annotation ‘skeletal system
development’ are coloured in green and those with GO annotation ‘regulation of ossification’ are coloured in blue. Genes in these three categories are
listed on the right. This figure represents ‘extracellular matrix organisation’, ‘skeletal system development’ and ‘regulation of ossification’ annotation
categories only, as genes with the annotations ‘ossification’ and ‘bone development’ are all contained within the other 3 categories. There were four
very highly upregulated genes (labelled on the plot). These are matrix metallopeptidase 1 (MMP1, FC = 23.00, pval = 6.09 × 10–6), leucine-rich repeat
containing G protein-coupled receptor 5 (LGR5, FC = 18.59, pval = 5.77 × 10–7), RAN binding protein 3-like (RANBP3L, FC = 18.08, pval = 1.81 × 10–9) and
unannotated transcript cluster, 17118303 (FC = 26.05, pval = 7.49 × 10–6). On further investigation it was found that this latter transcript cluster maps to
chromosomal location: chr7:94058513–94060553, which corresponds to exon 52 of the COL1A2 gene. LGR5 and RANBP3L have very similar expression
values and so the dots on the volcano plot for each gene are overlapping
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found in gastrula zinc finger protein XICGF57.1-like
(49 % sequence identity, E value = 6 × 10−126). In the
fruit fly, there was also partial homology to the ZNF25
C2H2 domain in the crooked legs protein, isoform B
(44 % sequence identity, E value = 1 × 10−86). The KRAB
domain was not present in these two proteins. These
results indicate that the KRAB domain of ZNF25 protein
is conserved in tetrapod vertebrates. Figure 7 shows a do-
main alignment of ZNF25 and homologs identified by the
BLAST analysis.
Discussion
This study has shown that a novel transcription factor,
ZNF25, has a role in the differentiation of hMSCs to
osteoblastic cells. We observed that expression of the
transcription factor ZNF25 increased steadily during OB
differentiation of hMSCs, and its deficiency significantly
decreased alkaline phosphatase levels in differentiating
osteoblastic cells. The ZNF25 protein is present in the
nuclei of mature osteoblastic cells and osteocytes in hu-
man bone. These results suggest that ZNF25 plays a role
in in osteoblast differentiation of hMSCs.
ZNF25 belongs to the Krueppel C2H2-type zinc-finger
protein family and contains 12 C2H2-type zinc fingers
and one KRAB domain [30]. The Krueppel-associated
box (KRAB) is a domain of around 75 amino acids that
is found in the N-terminal part of about one third of
eukaryotic Krueppel-type C2H2 zinc finger proteins
(KRAB-ZFPs). These KRAB-ZFPs make up the largest
family of zinc finger transcription factors in mammals
and are only found in tetrapod vertebrates [51]. The
KRAB-ZFP family has expanded greatly to include hun-
dreds of members in mammals [52]. The KRAB domain
acts as a transcriptional repressor by binding to core-
pressor proteins, whereas the C2H2 zinc-finger domains
bind DNA. The function of proteins in the KRAB family
include repression of RNA polymerase II and III pro-
moters and binding and splicing of RNA [51].
KRAB-zinc finger proteins are known to play important
roles during cell differentiation and development. Indi-
vidual members of one subfamily of KRAB zinc finger
genes (ZNF91) are restricted to specific hematopoietic
cell lineages and may play a role in lineage commit-
ment, possibly silencing transcription from nonlineage-
expressed genes [53]. One of the other KRAB zinc finger
proteins is involved in osteoblast differentiation. AJ18
(ZFP354C) was identified by Jhoen et al. as a repressor of
osteoblast differentiation in rat embryonic tibia and cal-
variae [54]. Overexpression of AJ18 suppressed RUNX2
activity and repressed the markers of osteoblast differenti-
ation ALP and, BGLAP. Our BLAST analysis confirmed
the KRAB domain is only found in tetrapod vertebrates.
Previous studies have reported that KRAB-ZFPs have ex-
panded to a large degree in mammals [52, 55].
Fig. 7 Domain alignment between ZNF25 and its homologs in mouse, chicken and xenopus. These are drawn approximately to scale. There were no
direct orthologs discovered in Zebrafish or in Drosophila. However the closest matching proteins in these species, that contain multiple C2H2 domains,
are shown. The KRAB domain is coloured in red and C2H2 domains are coloured in yellow. The length of each protein is denoted by numbers at the
start and end the protein. The Drosophila crooked legs protein is larger and is not drawn to the same scale
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The temporal expression profile of ZNF25 clustered
with profiles of other transcription factors known to be
involved in osteogenesis. These transcription factors
include SMAD5, FOS, and SNAI2. SMAD5 functions
synergistically with SMAD1 and RUNX2 to induce
osteoblast-specific gene expression in C2C12 cells [56].
FOS proteins heterodimerize with JUN proteins to form
the AP1 transcription factor complex, which is an im-
portant regulator of bone formation [57]. SNAI2 binds
to RUNX2 promoters in vivo and acts as a positive
transcriptional regulator in human osteoblasts [58].
Whilst the profile of ZNF25 expression does not allow
us to understand its exact timing in any transcription
factor cascade, its co-expression with the transcription fac-
tors, above, emphasizes its association with ostoegenesis.
To discover putative genes that are targets of ZNF25,
and thus suggest possible molecular mechanisms by
which ZNF25 affects osteoblast differentiation, we iden-
tified the genes that are differentially regulated following
siRNA-mediated knock down. Given that ZNF25 has a
KRAB domain, and is likely to be a transcriptional re-
pressor, we anticipated the upregulation of a number of
osteogenic genes. MMP1, RANBP3L and LGR5 showed
striking upregulation and are functionally related to
osteoblast differentiation.
MMP1 was initially described as a collagenase to de-
grade fibrillary collagen (type I, II and III) [59] and other
extracellular matrix proteins: fibronectin, aggrecan, lami-
nin, perlecan, and vitronectin [59]. MMP1 has also non-
extracellular matrix substrates (pro-TNFa, IGF, SDF1a
and MCP 1–4). Degradation of these substrates, such as
COL1A1, by increased MMP1 may lead to impaired extra-
celluar matrix levels and/or organization. Since ECM
abundance, structure and/or content may be important
triggers for mineralization, this may explain the apparent
impairment of in vitro formation of mineralized matrix.
RANBP3L has recently [60] been reported to be a nuclear
export factor for Smad1/5/8, which are effectors of canon-
ical BMP signaling. Canonical BMP signalling is tightly
regulated through reversible phosphorylation and nucleo-
cytoplasmic shuttling of Smad1/5 and 8. Interestingly,
Chen et al. [60] showed that overexpression of RANBP3L
blocks BMP-induced osteogenesis of mouse BM-MSCs,
while depletion of RANBP3L expression enhances
BMP-dependent MSC differentiation activity and tran-
scriptional responses. Further to this, the overexpres-
sion of RANBP3L in BM-MSCs was shown to result in
reduced ALP activity and alizarin red staining, a pheno-
type which is consistent to what we observed on knock-
down of ZNF25 and its resulting increase in RANBP3L
expression. However, Chen et al. [60] reported that
RANBP3L overexpression compromised the BMP-induced
expression of the preosteoblast marker RUNX2, whereas
we did not detect any changes in expression of RUNX2.
Thus it is likely that RANBP3L acts earlier in the differenti-
ation process than ZNF25. LGR5 is an orphan G-protein
coupled receptor and is a direct target of canonical Wnt
signaling. LGR5 potentiates the canonical Wnt signaling
pathway by binding to R-spondins [61]. LGR5 also a mouse
marker of stem cells in small intestine and colon [62].
Its relationship to osteoblast differentiation is currently
unknown.
Conclusions
In this study we have shown that the uncharacterized
transcription factor, ZNF25, has a role in the differenti-
ation of hMSCs to osteoblasts. ZNF25 appears to act as a
transcriptional repressor via a KRAB domain and we iden-
tified three potential targets of ZNF25, matrix metallopep-
tidase 1, leucine-rich repeat containing G protein-coupled
receptor 5 and RAN-binding protein 3-like. Future studies
will determine the role of this transcription factor in the
in vivo bone formation.
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